마커 테라퓨틱스(MRKR)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.14 (+2.70%), 시가총액 $0.02B, 52주 범위 $0.85 ~ $2.19.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was form
마커 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
마커 테라퓨틱스의 현재 주가는 $1.14 (+2.70%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
마커 테라퓨틱스의 시가총액은 약 $0.02B입니다.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indication